Primäres Knochenlymphom: Klinische Analyse von 17 Patienten in derselben Institution

2015 ◽  
Vol 2 (2) ◽  
pp. 90-91
Keyword(s):  
International Prognostic Index ◽  
Prognostic Index ◽  
Complete Response ◽  
Clinical Analysis ◽  
Single Institution ◽  
Primary Bone Lymphoma ◽  
Stadium Iv ◽  
Primary Bone ◽  
Bone Lymphoma

Primäre Knochenlymphome (primary bone lymphomas; PBL) machen weniger als 1% aller malignen Lymphome aus. Da in Japan erst wenige Studien zu PBL durchgeführt wurden, sind die Merkmale der PBL bei japanischen Patienten nicht vollständig geklärt. Wir analysierten retrospektiv 17 Patienten, bei denen zwischen 2001 und 2011 in unserer Einrichtung ein PBL diagnostiziert worden war. Der Altersmedian der Patienten betrug 60 Jahre. Elf Patienten hatten ein diffuses großzelliges B-Zell-Lymphom und 2 eine T-Zell-Lymphom-Histologie. Die Wirbelsäule war zum Zeitpunkt der Erstvorstellung am häufigsten betroffen. Bei 11 Patienten war die Krankheit im Stadium IV, und 11 Patienten wiesen laut dem International Prognostic Index (IPI) ein hohes oder mittleres bis hohes Risiko auf. 13 Patienten erreichten nach der initialen Therapie eine Vollremission (complete response; CR). Nach einer medianen Nachbeobachtungszeit von 31 Monaten betrug die 3-Jahres-Rate des Gesamtüberlebens (OS) und des progressionsfreien Überlebens 63,5 bzw. 49,9%. Eine lokal begrenzte Erkrankung, ein niedriges oder niedriges bis mittleres IPI-Risiko und eine CR nach initialer Therapie waren bei den PBL-Patienten mit einem guten Verlauf und signifikant mit einem besseren OS assoziiert. Eine Beteiligung der Wirbelsäule und der T-/NK-Zell-Phänotyp kommen bei japanischen PBL-Patienten häufiger vor als bei solchen kaukasischen Ursprungs. Übersetzung aus Hayase E, et al: Primary Bone Lymphoma: A Clinical Analysis of 17 Patients in a Single Institution. Acta Haematol 2015;134:80-85 (DOI: 10.1159/000375437)

scholarly journals Primary Bone Lymphoma: An Experience of a Regional Cancer Center from India

2020 ◽  
Vol 09 (04) ◽  
pp. 227-229
Author(s):  
Rohit Mahajan ◽  
Budhi Singh Yadav ◽  
Suresh Chander Sharma ◽  
Ankita Gupta ◽  
Shikhar Kumar
Keyword(s):  
International Prognostic Index ◽  
Prognostic Index ◽  
B Cell Lymphoma ◽  
Clinical Staging ◽  
Histologic Subtype ◽  
Primary Bone Lymphoma ◽  
Number Of Patients ◽  
Primary Bone ◽  
Hodgkin's Lymphomas ◽  
Bone Lymphoma

Abstract Background Primary bone lymphoma (PBL) is a rare disease, representing <5% of all extranodal non-Hodgkin’s lymphomas (NHLs). The optimal treatment strategy is still unclear. Here, we report our institutional outcome analysis of patients diagnosed with PBL. Materials and Methods From 2007 to 2014, the medical records of 22 patients with PBL were reviewed. Analysis was done for symptom-, patient-, disease-, and treatment-related characteristics. All patients were treated with chemotherapy with or without radiotherapy. Treatment response and impact of different prognostic factors on clinical outcome were analyzed. Results The median age of presentation was 44 years (range: 18–70 years). A total of 19 (86.4%) patients were ≤60 years of age and 3 (13.6%) patients were >60 years. Out of all, 18 were males and 4 were females. Ann Arbor clinical staging at diagnosis was Stage I in 13 (59.1%), Stage II in 3 (13.6%), Stage III in 2 (9.1%), and Stage IV in 4 (18.2%) patients. Spine was the most common site of involvement seen in 12 (54.5%) patients. Diffuse large B cell lymphoma histology was seen in 8 (36.4%) patients and 8 (36.4%) had high-grade NHL. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone was given to 20 (90.9%) patients, whereas 2 (9.1%) patients received cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab. Radiotherapy (30-40 Gy) was delivered to 19 (86.4%) patients. The median follow-up period was 40 months (range: 8–105 months). The overall response rate was 86.3% with complete response (CR) in 15 (68.1%) and partial response in 4 (18.2%) patients. Relapses were seen in three (13.5%) patients: two nodal, and one in the bone. Disease-free survival (DFS) and overall survival (OS) at 5 years were 56.6 and 72.7%, respectively. CR after initial treatment was associated with a significant better OS, 80 and 25%, respectively (p < 0.0001). Age, sex, stage, International Prognostic Index, histologic subtype, and number of sites had no significant influence on OS. Combining radiation therapy with chemotherapy (with or without rituximab) also did not improve the OS or DFS of patients. Conclusion In spite of small number of patients reported in this study, conventional chemotherapy remains an effective treatment option for patients with PBL. OS was found to be affected by the initial response to treatment.

Primary Bone Lymphoma: A Clinical Analysis of 17 Patients in a Single Institution

2015 ◽  
Vol 134 (2) ◽  
pp. 80-85 ◽  
Author(s):  
Eiko Hayase ◽  
Mitsutoshi Kurosawa ◽  
Hiroaki Suzuki ◽  
Kohei Kasahara ◽  
Tomohiro Yamakawa ◽  
...  
Keyword(s):  
Initial Treatment ◽  
Nk Cell ◽  
Cell Lymphoma ◽  
International Prognostic Index ◽  
Prognostic Index ◽  
B Cell Lymphoma ◽  
Cell Phenotype ◽  
Primary Bone Lymphoma ◽  
Primary Bone ◽  
Bone Lymphoma

Primary bone lymphoma (PBL) comprises less than 1% of all malignant lymphomas. Because few studies of PBL have been conducted in Japan, the characteristics of Japanese patients with PBL have not been fully elucidated. We retrospectively analyzed 17 patients diagnosed with PBL at our institution between 2001 and 2011. Median patient age was 60 years. Eleven patients had diffuse large B-cell lymphoma and 2 patients had T-cell lymphoma histology. The spine was the most frequently involved site at the time of presentation. There were 11 patients with stage IV disease and 11 patients with high or high-intermediate risk according to the International Prognostic Index (IPI). Thirteen patients achieved complete response (CR) after initial treatment. At a median follow-up of 31 months, the 3-year overall survival (OS) and progression free survival were 63.5 and 49.9%, respectively. Localized disease, low or low-intermediate IPI, and CR after initial treatment were associated with a good outcome in patients with PBL and significantly associated with a better OS. Spine involvement and T/NK-cell phenotype are more frequent in Japanese than in Caucasian patients with PBL.

scholarly journals Primary Bone Lymphoma: A New and Detailed Characterization of 28 Patients in a Single-Institution Study

2007 ◽  
Vol 37 (3) ◽  
pp. 216-223 ◽  
Author(s):  
Dai Maruyama ◽  
Takashi Watanabe ◽  
Yasuo Beppu ◽  
Yukio Kobayashi ◽  
Sung-Won Kim ◽  
...  
Keyword(s):  
Single Institution ◽  
Detailed Characterization ◽  
Primary Bone Lymphoma ◽  
Primary Bone ◽  
Bone Lymphoma

Primary bone lymphoma: Single institution experience

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 19515-19515
Author(s):  
G. Korpanty ◽  
D. G. Power ◽  
A. Treacy ◽  
G. P. McVey ◽  
C. O’Keane ◽  
...  
Keyword(s):  
Single Institution ◽  
Primary Bone Lymphoma ◽  
Primary Bone ◽  
Bone Lymphoma

Primary bone lymphoma: single institution case series

2008 ◽  
Vol 177 (3) ◽  
pp. 247-251 ◽  
Author(s):  
D. G. Power ◽  
G. P. McVey ◽  
G. Korpanty ◽  
A. Treacy ◽  
P. Dervan ◽  
...  
Keyword(s):  
Case Series ◽  
Single Institution ◽  
Primary Bone Lymphoma ◽  
Primary Bone ◽  
Bone Lymphoma

scholarly journals Belated Diagnosis of a Primary Bone Lymphoma of the Elbow: A Rare Case and Review of the Literature

2020 ◽  
pp. 100-107
Author(s):  
Michele Boffano ◽  
Nicola Ratto ◽  
Martina Rezzoagli ◽  
Andrea Conti ◽  
Pietro Pellegrino ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Rare Disease ◽  
Rare Case ◽  
Early Stage ◽  
Bone Lesions ◽  
Review Of The Literature ◽  
Primary Bone Lymphoma ◽  
Lytic Bone Lesions ◽  
Primary Bone ◽  
Bone Lymphoma

Primary non-Hodgkin bone lymphoma (PBL) is a rare disease that accounts for <2% of all lymphomas in adults. PBL can be monostotic or polyostotic, mainly causing destructive and lytic bone lesions frequently located in the femur, humerus, and pelvis. PBL is rarely considered a differential diagnosis of the osteolytic tumor. In addition, PBL is not uncommonly diagnosed with delay because patients do not experience symptoms nor show objective abnormalities in the early stage of disease. Here, we reported a 60-year-old woman with a PBL of the elbow.

scholarly journals Clinical characteristics and outcomes of primary bone lymphoma in Korea

2012 ◽  
Vol 47 (3) ◽  
pp. 213 ◽  
Author(s):  
So Yeon Kim ◽  
Dong-Yeop Shin ◽  
Seung-Sook Lee ◽  
Cheolwon Suh ◽  
Jae-Yong Kwak ◽  
...  
Keyword(s):  
Clinical Characteristics ◽  
Primary Bone Lymphoma ◽  
Primary Bone ◽  
Bone Lymphoma
Sign in / Sign up

Export Citation Format

Share Document